-
Most Popular
Search Results
240 results for MER
The Song Remains the Same
Despite Thursday’s reversals, nothing has changed the major trend of the market.
CCL Stock Is Staring at a Very Bleak Future
Due to coronavirus fears causing major disruptions to the cruise liner industry, CCL stock naturally suffered huge losses. But the volatility may not be over…
Slicing Through the Election Rhetoric
We’re a stone’s throw away from the November elections, and both John McCain and Barack Obama have upped the rhetoric about the state of the…
133 Blue-Chip Stocks Just Got New Quant Ratings
You see, as I write this, the S&P 500, the Dow and NASDAQ are all down 8.5%, 6.95% and 12.6%, respectively, for March. But the…
3 Cult-Like Stocks to Buy for Long-Term Gains
There are stocks and then there are cult-like stocks. These three are in the latter category for many reasons including making you money.
Novavax: Big Market Potential, Meaningful Stock Upside
Even after a 5,690% gain, NVAX stock looks positioned for further upside with the firm’s focus on bringing vaccines to low-income countries.
Novavax Stock Is Poised to Climb Further
NVAX stock seems positioned for further gains with the firm’s vaccine deliveries set to begin in early 2022.
Novavax Stock Got Merck-ed, but Don’t Dump Your Shares Now
NVAX stock still has plenty of value as Novavax has a rich and diverse clinical pipeline, including a promising influenza vaccine candidate.
Novavax Is the Ultimate Coronavirus Stock
Novavax has failed at late-stage clinical trials before, but if its COVID-19 vaccine even has 50% efficacy it could open up a huge global opportunity.
Investors Should View IBIO Stock Among Vaccine Wanna-be’s, Not Makers
IBIO stock has been acting like a potential COVID-19 vaccine producer, but it lacks contracts with leading providers and its own work remains at a…
Inovio Pharma’s Next Clinical Results Will be Binary for INO Stock
Inovio Pharma’s next clinical results will be a binary event for INO Stock. It will rise or fall based on its Phase 1 results due…
Add Inovio Stock to Your High-Growth Biotech Holdings
You can call INO a coronavirus stock, but it’s really much more than that.
Gilead’s Cash and the Coronavirus Make GILD Stock Look Cheap
Gilead Sciences rose to prominence with its hepatitis C drug. Now GILD stock is soaring on hopes for a coronavirus treatment.
iBio Stock Is Too Risky
IBIO stock gets attention because of iBio’s foray into treating the coronavirus, but investors who want that exposure should look elsewhere.
Gilead Sciences Pins Its Hopes on Remdesivir
Clinical trial results for Gilead’s remdesivir should come this month. If it’s effective, GILD stock could explode higher on the news.
Bet on INO Stock Beyond Its Promising Covid-19 Vaccine Developments
Inovio just launched its Phase 1 trials of INO-4800 for a vaccine. Should all go according to plan, INO could run to at least $20…
Focus on iBio’s Tech, Not Its Coronavirus Story
IBIO stock shot up in March on news that it might produce a coronavirus vaccine. However, its at-scale production tech is more interesting.
Don’t Buy Inovio Stock on Hopes for a Vaccine
Coronavirus hysteria on Wall Street is temporary. When it passes, INO stock could turn into a “look out below” situation.
Inovio Is Still Hot as the Coronavirus Spreads
INO stock still has some serious upside, thanks to its INO-4800. Inovio’s coronavirus vaccine takes the lead and is in preclinical trials.
5 Best Vanguard Funds to Buy for Target Date 2030 Retirement
You’re going to need some added oomph if you’ve got roughly 15-20 years before retirement. Here’s a look at some of the best Vanguard funds…
4 Big, Safe Dividend Plays for the Long Haul
Dividend ETFs are popular with investors, as they seek better performance than bonds provide. Here are four ETFs for the long haul.
6 – 10 of 240 results
